
Akums Drugs & Pharmaceuticals Limited


Working at Akums Drugs & Pharmaceuticals Limited
Company Summary
Overall Rating

13% above

Highly rated for 
Job security, Company culture, Salary
Work Policy




Top Employees Benefits
Rate your company
🤫 100% anonymous
How was your last interview experience?
About Akums Drugs & Pharmaceuticals Limited

Akums Drugs & Pharmaceuticals Limited serves as a pharmaceutical product manufacturer, providing an extensive array of offerings such as oral solids, oral liquids, injectables, cosmetics, ayurvedic, and nutraceuticals. Established in 2004, Akums operates as a pharmaceutical Contract Development and Manufacturing Organization (CDMO), delivering a comprehensive suite of pharmaceutical products and services both within India and internationally. As of September 30, 2023, the company's prominent clients include Alembic Pharmaceuticals, Alkem Laboratories, Cipla, Dabur India, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and others.
Akums Drugs & Pharmaceuticals Limited Ratings
Overall Rating
Category Ratings
Job security
Company culture
Salary
Skill development
Work-life balance
Promotions
Work satisfaction
Work Policy at Akums Drugs & Pharmaceuticals Limited
Akums Drugs & Pharmaceuticals Limited Reviews
Top mentions in Akums Drugs & Pharmaceuticals Limited Reviews
Compare Akums Drugs & Pharmaceuticals Limited with Similar Companies
![]() | ![]() Change Company | ![]() Change Company | ![]() Change Company | |
---|---|---|---|---|
Overall Rating | 4.4/5 based on 2k reviews | 4.0/5 based on 5.8k reviews ![]() | 4.1/5 based on 6.9k reviews ![]() | 5.0/5 based on 1 reviews |
Highly Rated for | Job security Skill development Salary | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | ![]() No critically rated category | ![]() No critically rated category | ![]() No critically rated category | ![]() No critically rated category |
Primary Work Policy | Work from office 94% employees reported | Work from office 82% employees reported | Work from office 73% employees reported | - |
Rating by Women Employees | 4.5 Good rated by 319 women | 4.0 Good rated by 442 women | 4.1 Good rated by 681 women | - no rating available |
Rating by Men Employees | 4.4 Good rated by 1.6k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 4.4 Good | 3.8 Good | 3.7 Good | 4.0 Good |
Akums Drugs & Pharmaceuticals Limited Salaries
Officer
Executive Assistant
Production Officer
QA Officer
Assistant Research Associate
Quality Control Officer
Quality Assurance Officer
QC Officer
Research Associate
Deputy Manager
Akums Drugs & Pharmaceuticals Limited Interview Questions
Interview questions by designation
Top Akums Drugs & Pharmaceuticals Limited interview questions and answers
Akums Drugs & Pharmaceuticals Limited Jobs
Akums Drugs & Pharmaceuticals Limited News
Akums Drugs and Pharma Q3 Results: Adjusted Profit Rises 15% To Rs 66.3 Crore
- Akums Drugs and Pharmaceuticals reported a 15% rise in adjusted profit to Rs 66.3 crore in Q3 2024.
- Total income of the company stood at Rs 1,025 crore in the quarter.
- Akums Drugs and Pharmaceuticals secured a 200-million-euro contract for the manufacture and supply of products in European markets.
- The company in-licensed novel products of Triple hair and Caregen in the dermatology and metabolic segment.

Raymond, Azad Engineering To Mahanagar Gas — These Companies Will Trade T+0 From Jan. 31
- Raymond Ltd., Azad Engineering Ltd., and Mahanagar Gas Ltd. are among the 100 companies eligible for T+0 settlement from Jan. 31.
- The T+0 settlement cycle, allowing shares to be credited on the same day of trade, will be implemented in a phased manner.
- Allied Blenders and Distillers Ltd., Aether Industries Ltd., Akums Drugs and Pharmaceuticals Ltd., Ceat Ltd., Edelweiss Financial Services Ltd. and Glenmark Life Sciences Ltd. are also part of the first phase of T+0 settlement.
- The T+0 settlement cycle aims to bring cost and time efficiency, transparency in charges, and strengthen risk management at clearing corporations.

Akums Drugs Share Price Falls Following Income Tax Search
- Akums Drugs & Pharmaceuticals Ltd. saw a 6% fall in share price after the Income Tax Department conducted a search at their offices and manufacturing units.
- Akums Drugs stated that it is cooperating with the IT department during the search and assured that business operations will continue as usual.
- In December, Akums Drugs signed an agreement with a global pharma company to manufacture and supply pharmaceutical formulations in the European market.
- The share price of Akums Drugs fell to Rs 585.20 apiece, the lowest since December, and is now trading 4.82% lower at Rs 595.50 apiece.

Top Funding Wrap of the Week – 23 Dec – 27 Dec 2024
- Akums Group signs a €200 million deal to produce and supply pharmaceutical products for the European market.
- Zaggle Prepaid Ocean Services raises ₹595 crore through a qualified institutional placement.
- Metropolitan Stock Exchange plans to raise ₹238 crore from investors including Billionbrains Garage Ventures, Groww's parent company, Zerodha's Rainmatter Investments, Securocorp Securities India, and Share India Securities.
- EPACK Prefab raises $20 million in its first funding round from GEF Capital Partners.

Akums Group Secures €200 Million Deal to Expand in Europe
- Akums Group, India's largest contract manufacturing company, has secured a €200 million deal to expand in Europe.
- The deal involves producing and supplying pharmaceutical products for the European market.
- Akums will receive an upfront payment of €100 million to help with product development and European regulatory approvals.
- The partnership aims to strengthen Akums' presence in Europe and align with its long-term strategic objectives.

Akums inks €200 million agreement with a global pharma company for the European market
- Akums, a contract manufacturing and development organisation (CDMO), has signed a €200 million agreement with a global pharma company for the European market.
- Akums will produce and supply multiple SKUs of oral liquid formulations, while the partner company will market them in various European countries.
- The agreement aims to boost Akums' domestic manufacturing capabilities for global markets and is expected to begin commercial supply in 2027, continuing till 2032.
- Akums will initiate the European approval process for its oral liquid manufacturing facility, with site and product dossier approvals expected by end 2026.

Akums inks €200 million agreement for the European market
- Akums, a contract manufacturing and development organisation (CDMO), has entered into a €200 million agreement for the European market.
- Under the agreement, Akums will produce and supply multiple SKUs of oral liquid formulations, while the partner company will market them in various European countries.
- The agreement aligns with Akums' plans to expand in regulated markets and boost domestic manufacturing capabilities for global markets.
- Commercial supply of these products is expected to begin in 2027, and the European approval process for Akums' oral liquid manufacturing facility will commence.

Akums Drugs Inks Rs 1,760-Crore Pact To Make, Supply Oral Liquid Formulation To European Countries
- Akums Drugs and Pharmaceutical Ltd. has signed a pact with a global pharma company to manufacture and supply selected pharmaceutical formulations in European market.
- Akums group will manufacture and supply multiple SKUs of oral liquid formulation to be marketed in multiple European countries.
- The commercial supply of these products from Akums will commence in 2027.
- The composite value of the agreement is approx. Euro 200 million or Rs 1,760 crores.

Buy, Sell Or Hold: Tata Motors, Akums Drugs, IOC, BEL — Ask Profit
- Experts from SBICap Securities and Kushbohra.com offer crucial investment advice on whether to buy, sell, or hold shares of companies like Tata Motors, Akums Drugs, and Bharat Electronics Ltd.
- Tata Motors (CMP: Rs 783.65) - Experts recommend holding the stock as it looks favorable after a correction, with a fair value of around Rs 2,000 in the next 12-18 months.
- Akums Drugs (CMP: Rs 630) - Experts suggest buying the stock as strong numbers have been seen in the contract development and manufacturing organization front.
- Swan Energy (CMP: Rs 605.75) - Experts advise holding the stock as the recent trigger of acquiring Reliance Naval defense business can potentially result in high returns in the next two-three years.

Akums Drugs & Pharmaceuticals Limited Perks & Benefits
Akums Drugs & Pharmaceuticals Limited Subsidiaries
Akumentis Healthcare
Pure & Cure Healthcare
Maxcure Nutravedics
Compare Akums Drugs & Pharmaceuticals Limited with




















Contribute & help others!
Companies Similar to Akums Drugs & Pharmaceuticals Limited










Akums Drugs & Pharmaceuticals Limited FAQs
Reviews
Interviews
Salaries
Users/Month